Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47626/2237-6089-2024-1010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the Role of TBK1 as a Novel Biomarker in Obstructive Sleep Apnea Syndrome.
Sleep
January 2025
Department of Clinical Nutrition, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Intervention is Needed in PCOS for Prevention of Cardiovascular Diseases.
Eur J Prev Cardiol
January 2025
Saint Luke's Mid America Heart Institute, University of Missouri 4321 Washington Street, Suite 2400, Kansas City, MO 64111, USA.
Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified.
Brain
January 2025
Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
Reply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. 2024, , 1607".
J Clin Med
January 2025
Department of Surgery, Formerly of Royal Marsden Hospital, London SW3 6JJ, UK.
We note with interest the commentary by Pennington and Thompson (P&T) regarding our detailed update on the management of primary cutaneous melanoma in 2024 [...
View Article and Find Full Text PDFBeyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.
J Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!